vs
Side-by-side financial comparison of CG Oncology, Inc. (CGON) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $2.3M, roughly 2.4× CG Oncology, Inc.). Taysha Gene Therapies, Inc. runs the higher net margin — -507.8% vs -1779.0%, a 1271.3% gap on every dollar of revenue. On growth, CG Oncology, Inc. posted the faster year-over-year revenue change (409.2% vs 171.3%).
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
CGON vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3M | $5.5M |
| Net Profit | $-41.3M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | -2097.3% | -516.0% |
| Net Margin | -1779.0% | -507.8% |
| Revenue YoY | 409.2% | 171.3% |
| Net Profit YoY | -29.9% | -48.3% |
| EPS (diluted) | $-0.52 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3M | $5.5M | ||
| Q3 25 | $1.7M | $0 | ||
| Q2 25 | $0 | $2.0M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $456.0K | $2.0M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | $529.0K | $3.4M |
| Q4 25 | $-41.3M | $-27.9M | ||
| Q3 25 | $-43.8M | $-32.7M | ||
| Q2 25 | $-41.4M | $-26.9M | ||
| Q1 25 | — | $-21.5M | ||
| Q4 24 | $-31.8M | $-18.8M | ||
| Q3 24 | — | $-25.5M | ||
| Q2 24 | — | $-20.9M | ||
| Q1 24 | $-16.9M | $-24.1M |
| Q4 25 | -2097.3% | -516.0% | ||
| Q3 25 | -3069.0% | — | ||
| Q2 25 | — | -1347.1% | ||
| Q1 25 | — | -930.5% | ||
| Q4 24 | -8344.1% | -985.8% | ||
| Q3 24 | — | -1448.4% | ||
| Q2 24 | — | -1915.4% | ||
| Q1 24 | -4247.4% | -713.3% |
| Q4 25 | -1779.0% | -507.8% | ||
| Q3 25 | -2629.5% | — | ||
| Q2 25 | — | -1353.6% | ||
| Q1 25 | — | -935.2% | ||
| Q4 24 | -6973.7% | -929.0% | ||
| Q3 24 | — | -1427.5% | ||
| Q2 24 | — | -1882.0% | ||
| Q1 24 | -3200.8% | -705.4% |
| Q4 25 | $-0.52 | $-0.08 | ||
| Q3 25 | $-0.57 | $-0.09 | ||
| Q2 25 | $-0.54 | $-0.09 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | $-0.47 | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | $-0.36 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $742.2M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $752.6M | $246.9M |
| Total Assets | $791.6M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $742.2M | $319.8M | ||
| Q3 25 | $680.3M | $297.3M | ||
| Q2 25 | $661.1M | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | $742.0M | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | $566.5M | $124.0M |
| Q4 25 | $752.6M | $246.9M | ||
| Q3 25 | $687.6M | $219.0M | ||
| Q2 25 | $670.4M | $248.7M | ||
| Q1 25 | — | $55.1M | ||
| Q4 24 | $733.4M | $71.5M | ||
| Q3 24 | — | $88.8M | ||
| Q2 24 | — | $108.9M | ||
| Q1 24 | $568.9M | $53.8M |
| Q4 25 | $791.6M | $343.3M | ||
| Q3 25 | $729.9M | $316.6M | ||
| Q2 25 | $701.4M | $333.3M | ||
| Q1 25 | — | $138.4M | ||
| Q4 24 | $754.8M | $160.4M | ||
| Q3 24 | — | $180.2M | ||
| Q2 24 | — | $200.4M | ||
| Q1 24 | $579.1M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-36.2M | $-26.7M |
| Free Cash FlowOCF − Capex | $-36.2M | — |
| FCF MarginFCF / Revenue | -1560.0% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-124.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-36.2M | $-26.7M | ||
| Q3 25 | $-38.9M | $-24.2M | ||
| Q2 25 | $-28.0M | $-20.2M | ||
| Q1 25 | — | $-22.0M | ||
| Q4 24 | $-20.7M | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.5M | ||
| Q1 24 | $-26.0M | $-19.8M |
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-39.0M | $-24.3M | ||
| Q2 25 | $-28.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-20.9M | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | $-26.0M | $-19.9M |
| Q4 25 | -1560.0% | — | ||
| Q3 25 | -2340.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4577.0% | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | -4919.5% | -584.5% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 45.8% | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | 2.3% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
